Cite
HARVARD Citation
Poulin, Y. et al. (2020). Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. pp. 1500-1509. [Online].